Equities

IGC Pharma Inc

IGC Pharma Inc

Actions
IndustrialsConstruction and Materials
  • Price (USD)0.40
  • Today's Change-0.007 / -1.60%
  • Shares traded314.67k
  • 1 Year change+17.65%
  • Beta1.7092
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimer’s. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer’s cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

  • Revenue in USD (TTM)1.22m
  • Net income in USD-14.15m
  • Incorporated2005
  • Employees61.00
  • Location
    IGC Pharma Inc2405 York Road, Suite 201LUTHERVILLE-TIMONIUM 21093-2264United StatesUSA
  • Phone+1 (301) 983-0998
  • Fax+1 (240) 465-0273
  • Websitehttps://igcpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Neurosense Therapeutics Ltd0.00-11.48m24.87m14.00---------0.8568-0.85680.00-0.0150.00----0.00-157.09---208.80-----------------------205.37------
Forte Biosciences Inc0.00-31.48m25.34m9.00--0.7163-----1.19-1.190.000.97190.00----0.00-77.74-72.06-84.92-82.27-------491,850.00----0.00-------126.79---46.29--
Arca Biopharma Inc0.00-5.34m25.52m4.00--0.6894-----0.3704-0.37040.002.550.00----0.00-13.19-27.78-13.49-29.38------------0.00------46.21------
Lisata Therapeutics Inc0.00-20.84m25.92m25.00--0.5281-----2.58-2.580.005.910.00----0.00-32.63-45.97-36.16-50.47------------0.00------61.57------
Biora Therapeutics Inc18.00k-122.17m26.07m54.00------1,448.56-9.56-9.590.0016-5.070.0004--0.0219333.33-251.08---63,963.88-------678,727.80-----------75.54--72.65------
Sensei Biotherapeutics Inc0.00-34.10m26.32m27.00--0.405-----1.21-1.210.002.590.00----0.00-35.38-47.03-38.31-54.33------------0.0247------29.82--42.16--
IGC Pharma Inc1.22m-14.15m26.43m61.00--2.82--21.73-0.2479-0.24790.02170.1420.07760.20847.0919,934.43-90.30-33.35-100.90-35.8451.408.74-1,163.24-410.260.8564--0.0153--129.47-16.1123.38--25.28--
Oncternal Therapeutics Inc785.00k-39.48m26.64m27.00--0.8829--33.93-13.44-13.440.267210.190.0149----29,074.07-74.93-49.40-85.36-54.51-----5,029.17-1,342.98----0.00---47.32--10.62------
MEI Pharma Inc72.65m19.84m26.65m46.001.340.4481.320.36692.982.9810.908.930.6425--25.471,579,304.0017.55-25.3120.31-28.59----27.32-122.05----0.00--19.9597.5641.53------
Ayala Pharmaceuticals Inc-100.00bn-100.00bn27.29m14.00---------------1.30-----------56.14---70.04-------462.10---------92.28-53.9213.87---46.58--
Sol Gel Technologies Ltd1.55m-27.24m27.30m36.00--0.7065--17.57-1.02-1.020.05741.390.0338--0.377443,166.67-59.27-31.60-64.80-35.49-----1,752.77-135.76----0.00---59.9864.50-82.52---33.78--
Unity Biotechnology Inc0.00-52.53m27.53m32.00--0.662-----3.65-3.650.002.480.00----0.00-51.08-51.33-58.28-57.56-------7,431.69---159.240.00---95.07-29.781.31---43.65--
Lipocine Inc-2.85m-16.35m27.64m17.00--1.36-----3.11-3.11-0.54173.83-0.0942-----167,695.30-54.02-39.32-58.16-45.87-------442.26----0.00---670.16---51.99------
Brainstorm Cell Therapeutics Inc0.00-16.63m27.66m43.00---------0.4367-0.43670.00-0.0570.00----0.00-175.67-108.79-907.12-197.40--------------------0.736---30.59--
Data as of Mar 28 2024. Currency figures normalised to IGC Pharma Inc's reporting currency: US Dollar USD

Institutional shareholders

3.61%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 2023717.88k1.13%
The Vanguard Group, Inc.as of 31 Dec 2023630.22k0.99%
Geode Capital Management LLCas of 31 Dec 2023324.30k0.51%
SSgA Funds Management, Inc.as of 31 Dec 2023184.11k0.29%
Dearborn Partners LLCas of 31 Dec 2023116.71k0.18%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 202371.36k0.11%
Bridgeway Capital Management LLCas of 31 Dec 202369.00k0.11%
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 202365.50k0.10%
Virtu Americas LLCas of 31 Dec 202360.72k0.10%
Group One Trading LPas of 31 Dec 202360.46k0.10%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.